Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 15/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 12/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 12/20 | 0.52 |
| ▸ | REN | P00797 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715141 | 0.87 | EPHX2 (0.63) | MMP3EPHX2MMP1MMP9MMP2 | |
| SCHEMBL5528697 | 0.83 | CTSK (0.57) | MMP3EPHX2MMP1MMP9MMP2 | |
| SCHEMBL5523633 | 0.80 | EPHX1 (0.57) | MMP3EPHX2MMP1MMP2 | |
| SCHEMBL4144621 | 0.79 | MMP3 (0.50) | MMP3EPHX2MMP1MMP9MMP2 | |
| SCHEMBL7144493 | 0.78 | EPHX2 (0.61) | MMP3EPHX2MMP1MMP2 | |
| SCHEMBL7358712 | 0.78 | EPHX2 (0.61) | MMP3EPHX2MMP1MMP2 | |
| SCHEMBL13073340 | 0.78 | EPHX2 (0.61) | MMP3EPHX2MMP1MMP2 | |
| SCHEMBL5520607 | 0.76 | CTSK (0.55) | MMP3EPHX2MMP1MMP2 | |
| SCHEMBL7353859 | 0.75 | METAP2 (0.65) | MMP3EPHX2MMP1MMP2 | |
| Hydrochloric Acid SCHEMBL7361806 | 0.74 | METAP2 (0.63) | MMP3EPHX2MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1248612-B1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | disclosed |
| EP-1248612-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-09-07 | — | — | EP | disclosed |
| US-6525036-B2 | Treating post-menopausal osteoporosis. | MERCK & CO., INC. | 2003-02-25 | — | — | US | disclosed |
| EP-1248612-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-10-16 | — | — | EP | disclosed |
| US-20020052378-A1 | Novel compounds and compositions as protease inhibitors | Celera Corporation | 2002-05-02 | — | — | US | disclosed |
| WO-2001049288-A9 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001049288-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052378-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, CTRL, SPINT2 | MMP3 105/4885EPHX2 882/4885MMP1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.